


You're taking an important step. LUCEMYRA MAY HELP.



- You've made the decision to stop taking opioids and go through opioid withdrawal with LUCEMYRA. Here is what you can expect while on treatment¹
- You'll be dealing with some physical symptoms over the next few days, but you and your doctor have made a choice that may help—**LUCEMYRA is the first and only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal to facilitate abrupt discontinuation¹**

Here Is What You Can Expect During Your Treatment

Most Common Opioid Withdrawal Symptoms Include²:

- Aches and pains
- Stomach cramps
- Feeling sick
- Muscle spasms/twitching
- Insomnia/problems sleeping
- Feelings of coldness/chills
- Muscular tension
- Heart pounding
- Runny eyes
- Yawning

In Clinical Studies¹:

- LUCEMYRA improved symptom relief when it was needed most¹

DAY 1



Patients should **start to feel** some symptom relief

DAY 2



Patients should **experience an improvement** in symptom relief

DAY 3



Patients should **continue to feel improvement** in symptom relief, as withdrawal symptoms continue to decrease

- LUCEMYRA continued to be effective through Day 7 of treatment¹

Added Help with the LUminate Support App

- Support and encouragement can be critical while taking LUCEMYRA
- The LUminate Support App provides support as you go through opioid withdrawal with:
 - **Dose Tracking/Reminders**
 - **Supportive messages each day of treatment**
 - **Symptom Library** (including advice and tips for relief)
 - **Meditation Timer**



**NO SIGN-UP
REQUIRED**



Download on the
App Store

GET IT ON
Google Play

Indication

LUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Important Safety Information

LUCEMYRA will not stop you from craving opioids.

LUCEMYRA is not an opioid and will not produce the effects seen when taking opioids.

LUCEMYRA may lessen the severity of your symptoms, but it may not completely prevent them.

Please see additional Important Safety Information on reverse side and the accompanying full Prescribing Information and Patient Information.

NEW
Lucemyra[™]
(lofexidine) tablets 0.18 mg

Relieve the symptoms, retake control

Dosing You Can Do at Home

Example of a LUCEMYRA Prescription¹

3 TABLETS

4 TIMES

7 DAYS

- LUCEMYRA dosing is usually three tablets taken orally, four times a day, for 5-7 days, followed by a gradual reduction in dosing over 2-4 days¹
 - **Make sure you follow the exact dosing instructions provided by your doctor**
- Be sure to **wait 5 to 6 hours** between each dose¹
- LUCEMYRA can be taken **with or without food**¹
- LUCEMYRA can be **taken for up to 14 days** if you and your doctor decide that you need continued symptom relief¹
- **Do not** stop taking LUCEMYRA without first talking to your doctor

LUCEMYRA is not a treatment for Opioid Use Disorder (OUD), which is also called opioid addiction. If you have been diagnosed with OUD, your doctor may prescribe LUCEMYRA as part of a complete treatment program for your OUD. This program continues after LUCEMYRA treatment is completed and may also include maintenance medications combined with behavioral counseling.

Learn about Possible Savings on Your LUCEMYRA Prescription at [LUCEMYRA.com](https://www.lucemyra.com)

- Savings could be automatically applied to your co-pay

Important Safety Information (Continued)

After a period of not using opioids, you may be more sensitive to the effects of lower amounts of opioids. Taking opioids in amounts that you used before stopping opioid use, whether with or without LUCEMYRA, can lead to overdose and death. It is important that you, your family, and the people closest to you are aware of this increased risk of overdose.

Alcohol, barbiturates, and benzodiazepines should be used with caution while taking LUCEMYRA as serious side effects may occur. Tell your healthcare provider if you have ever been diagnosed with kidney disease or liver disease.

LUCEMYRA may cause low blood pressure or slower heart rate. Tell your healthcare provider if you have ever been diagnosed with low blood pressure, slow heart rate, any other cardiac abnormality (including prior diagnosis or family history of long QT syndrome), or if you have had a heart attack.

Tell your healthcare provider about all medications you are taking. LUCEMYRA should be used with caution with any medications that decrease pulse or blood pressure.

Watch for signs of a drop in your blood pressure or heart rate, including dizziness, lightheadedness, or feelings of faintness either when sitting or if you quickly stand up. If you experience these symptoms, call your healthcare provider and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider.

It is important to stay hydrated while taking LUCEMYRA during opioid discontinuation or withdrawal.

The most common side effects seen with LUCEMYRA are low blood pressure or symptoms such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth.

Talk to your healthcare provider before taking other medications for individual symptoms of withdrawal (such as pain relievers, sleep aids, or medications for upset stomach). Your healthcare provider will tell you whether it is safe to take LUCEMYRA with other medications you may be prescribed during opioid discontinuation (such as buprenorphine/naloxone, methadone, naltrexone).

LUCEMYRA should not be stopped abruptly. Consult your healthcare provider before stopping or reducing your LUCEMYRA dose.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-833-LUCEMYRA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on reverse side and the accompanying full Prescribing Information and Patient Information.

References: 1. LUCEMYRA™ (lofexidine) [Prescribing Information]. Louisville, KY: US WorldMeds, LLC; 2018. 2. Vernon MK, Reinders S, Mannix S, et al. Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification. *Addict Behav.* 2016;60:109-116.

US WorldMeds

US WorldMeds, LLC
4441 Springdale Road
Louisville, KY 40241

Under License from Britannia Pharmaceuticals Ltd.

US WorldMeds, LLC is the exclusive licensee and distributor of LUCEMYRA in the United States and Its territories.

©2018. LUCEMYRA and LUMinate are trademarks of US WorldMeds, LLC. USWM-LUC100A-0718

NEW
Lucemyra[™]
(lofexidine) tablets 0.18 mg

Relieve the symptoms, retake control